Biogen reported that its investigational anti-tau therapy diranersen, developed with Ionis Pharmaceuticals, slowed cognitive decline by 38% after two years in patients with early Alzheimer's disease receiving the 60 mg twice-yearly dose, compared with 26% at 18 months. The Phase II findings, presented at the Clinical Trials on Alzheimer's Disease conference, were measured using the Clinical Dementia Rating–Sum of Boxes (CDR-SB), with improvements reported across five of six cognitive and functional measures. Higher doses previously showed weaker clinical responses despite greater tau reduction, and two-year tau-imaging results were not yet available. Biogen is discussing Phase III trial design with regulators.
Reuters
Why it matters strategically
Tau reduction may offer a therapeutic strategy distinct from established amyloid-targeting treatments.
However, the nonmonotonic dose-response relationship is particularly important: greater biomarker suppression did not necessarily correspond to greater clinical benefit.